Key statistics
On Thursday, Lyell Immunopharma Inc (LYEL:NSQ) closed at 0.9166, 7.84% above its 52-week low of 0.85, set on Oct 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.04 |
Low | 0.9165 |
Bid | 0.9166 |
Offer | 0.98 |
Previous close | 1.03 |
Average volume | 1.34m |
---|---|
Shares outstanding | 279.22m |
Free float | 226.28m |
P/E (TTM) | -- |
Market cap | 287.60m USD |
EPS (TTM) | -0.8013 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
- Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
- Lyell Immunopharma Completes Acquisition of ImmPACT Bio
- Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
- Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
- Lyell Immunopharma Announces Participation in September Investor Conferences
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
- Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
More ▼